Executive SummaryHubert Peltier to Sterling Research Group as exec VP for clinical and regulatory affairs worldwide. Since leaving Merck in 1986, Peltier has served on the Research Group's board of scientific advisors
You may also be interested in...
Number one ask is for congressional pressure to centralize rare disease expertise at the agency, but advocates also are preparing legislation that would mandate the new center.
FDA’s food, dietary supplement and cosmetics division seeks funding to support its artificial intelligence capabilities, including post-market surveillance and speedy interventions in instances where safety issues arise. Also of note, the agency cites UV filters’ effects on the skin microbiome as a research priority in its fiscal 2021 budget justification to Congress.
Catering to patients can help make clinical trials more accessible and useful, presenters argued at a recent conference.